Insilico Biotechnology AG. (7/28/21). "Press Release: Prominent Scientist Professor John Bagterp Jørgensen Joins Insilico Scientific Advisory Board". Stuttgart.

	Organisation	Technical University of Denmark (DTU)
	Product	digital twin (simulation software / virtual reality (VR))
	Product 2	biopharmaceutical production technology (biomanufacturing)
	Person	Jørgensen, John Bagterp (Technical Univ of Denmark 202107 Professor at Dept of Applied Mathematics + Computer Science)

Insilico Biotechnology AG announces that Professor John Bagterp Jørgensen is joining its Scientific Advisory Board to enrich the scientific capabilities of the company achieving the desired growth and innovation.

Professor Jørgensen along with other distinguished scientists among Insilico’s Scientific Advisory Board will support the company to reach its goal expanding its technology to cover new areas within the biopharmaceutical and the biotechnology industry.

Having extensive research experience as a Professor at the Department of Applied Mathematics and Computer Science at the Technical University of Denmark (DTU), Prof. Jørgensen will support Insilico developing innovative solutions, and opening up new perspectives. His significant contribution in Model Predictive Control research will greatly enhance Insilico’s efforts to provide its customers with new manufacturing solutions, towards the Smart Biofactory vision.

Klaus Mauch, CEO of Insilico, says: "Prof. Jørgensen will be a great addition to our Scientific Advisory Board that supports our research and development team. Insilico will greatly benefit from his broad research experience in simulation, mathematical modelling, and process control. His contribution will strengthen our efforts to better serve the biopharmaceutical industry to achieve advanced biomanufacturing process control.“

About Insilico

Insilico Biotechnology AG develops and delivers predictive Digital Twins to advance biopharmaceutical process development and manufacturing. Insilico Digital Twins of cell culture processes lead to superior productivity, product quality and process robustness. Ground breaking predictive power is achieved by exploiting process data using artificial intelligence and biochemical networks. As a result, Insilco’s unique approach substantially reduces experimental effort, costs of goods and time to market. Leading biopharmaceutical companies worldwide use Insilico Digital Twins for cell line development, media design and process control. Founded in 2001, Insilico Biotechnology is a privately held company based in Stuttgart, Germany.

Record changed: 2023-06-05

Picture Berlin Partner Top News CareSyntax Raises $61m for Bio Cheese 650x200px

More documents for Yokogawa (Group)

[1] Insilico Biotechnology AG. (8/24/21). "Press Release: Insilico Biotechnology AG Participates in Inno4vac, a European new public-private partnership to innovate vaccine development". Stuttgart....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)